For UK Healthcare Professionals only
The patients profiles shown below may remind you of similar patients you have in your consultancy. Read the patient profiles and discover how Praluent® helps to reduce the risk of CV events for ACS patients with uncontrolled LDL-C1.
Susan has type 2 diabetes and had her second cardiac event 4 months ago. ~1 in 6 patients like Susan had a MACE over a median of 2.8 years2.
Read more about Susan
Susan was diagnosed with type 2 diabetes 12 years ago. She had her first MI aged 59 years following her husband’s death and a second event 4 months ago.
Susan meets the NICE criteria for prescribing PRALUENT®8
Read the results of the Odyssey outcomes trial and find out how Praluent® helps in reducing CV events post ACS by lowering LDL-C.
* Atorvastatin does not have UK marketing authorisation for secondary prevention of CVD.
The prescriber should follow relevant professional guidance taking full responsibility for the decision.
Not real patients, for illustrative purposes only
Dominic is 58 years old and has just had his second MI.
~1 in 11 patients like Dominic had a another event within one year3.
Read more about Dominic
At 54 years old, Dominic experienced an episode of unstable angina.
At 58 years old, Dominic has experienced a second ACS event.
Read the results of the Odyssey outcomes trial and find out how Praluent® helps in reducing CV events post ACS by lowering LDL-C.
* Atorvastatin does not have UK marketing authorisation for secondary prevention of CVD.
The prescriber should follow relevant professional guidance taking full responsibility for the decision.
Not real patients, for illustrative purposes only
Mary has hypercholesterolaemia and had a recent ACS event.
~1 in 2 FH patients like Mary will had at least 1 CV event in the next 10 years4.
Read more about Mary
Mary has FH, confirmed by genetic testing 4 years ago, and recently had an episode of UA.
She is careful with her diet and exercises intensely.
Read the results of the Odyssey outcomes trial and find out how Praluent® helps in reducing CV events post ACS by lowering LDL-C.
* Atorvastatin does not have UK marketing authorisation for secondary prevention of CVD.
The prescriber should follow relevant professional guidance taking full responsibility for the decision.
Not real patients, for illustrative purposes only
Ajay is 65 and has suffered his first heart attack.
~1 in 16 patients like Ajay may have an event within the first year post ACS3.
Read more about Ajay
Ajay was admitted to hospital 6 months ago with a STEMI aged 65 years. He was treated by coronary angiography, with follow-on primary PCI and discharged.
Read the results of the Odyssey outcomes trial and find out how Praluent® helps in reducing CV events post ACS by lowering LDL-C.
* Atorvastatin does not have UK marketing authorisation for secondary prevention of CVD.
The prescriber should follow relevant professional guidance taking full responsibility for the decision.
Not real patients, for illustrative purposes only
Not real patients, for illustrative purposes only
Do you want more information?
Request a representative to contact you here [request a visit link] or sign-up to receive updates here [keep in touch with Sanofi link].
Primary hypercholesterolaemia and mixed dyslipidaemia9
Praluent® is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet :
Established atherosclerotic cardiovascular disease9
Praluent® is indicated in adults with established atherosclerotic cardiovascular disease to reduce cardiovascular risk by lowering LDL-C levels as an adjunct to correction of other risk factors :